Impact of microparticles in cancer progression

Blood platelets are the principal source of cells known to shed small extracellular vesicles which package biologically active molecules. We have recently identified a new type of these vesicles (called microparticles/MPs) that contain mitochondria, which represent the energy producing motors for living cells. We have also discovered that MPs preferentially bind and internalize into leukemia cells to transfer their contents. As a result, recipient cancer cells gain energy producing capacity, which leads to increased cancer processes.

Identifying a novel role for the Von Hippel-Lindau protein in phosphoinositide metabolism and its potential as a personalized therapeutic strategy in renal cell carcinoma

Overview. There are 6,600 adults in Canada that will be diagnosed with kidney cancer in 2020. Renal Cell Carcinoma incidence has increased in the last 20 years particularly in developed countries. Unfortunately, these tumors are asymptomatic and 30% of patients present metastases at diagnosis. There is no curative treatment for metastatic RCC and it is crucial to develop new approaches to treat this disease. Research progress. We work on novel therapeutic strategies to treat RCC. Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is an early event reported in up to 90% of RCC.

Liquid biopsy for the discovery of new methods of cancer diagnosis and new treatment strategies - Year two

Despite the improvements in cancer diagnostic and treatment, cancer is still a leading cause of death in Canada with 30% of all deaths. Some cancers, like pancreatic cancer (PC), still have poor survival rates due to the lack of early diagnosis and good prognostics markers. The Atlantic Cancer Research Institute (ACRI) has developed a proprietary technology to capture extracellular vesicles (EVs) from various biofluids with the goal to deliver precision medicine solutions through liquid biopsy technologies.